Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease: MARINER

NCT05575037 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT05575037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05575037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease: MARINER
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 1, 2023
Completion date
December 30, 2026
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aspirin-exacerbated respiratory disease, aspirin-sensitive asthma with nasal polyps, asthma, aspirin-induced, nasal polyps